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Aims: This study aims to investigate the relationship between plasma endothelin-1 (ET-1) concentrations, ET-1
gene polymorphisms in loci rs5370, rs1630736, 3A/4A and clinical features of primary nephrotic syndrome
(NS) in children.
Materials and methods: Thirty-six children with primary NSwere selected as case group, and 94 healthy children
were selected as control group. All subjects were genotyped for three single nucleotide polymorphisms (SNPs)
(rs5370, rs10478694 [3A4A] and rs 1630736) in the ET-1 gene by gene sequencing. The plasma ET-1 concentra-
tions were measured using a radio-immunoassay.
Key ﬁndings: Plasma ET-1 concentrations were higher in NS patients (P = 0.007) as compared to healthy chil-
dren. The allele frequencies between control and NS patients were signiﬁcantly different only with respect to
the rs10478694 SNP of the ET-1 gene. The allele frequencies between control and NS patients for the rs5370
SNP showed a trend towards difference (P= 0.057). Plasma cholesterol in NS patients is associated with both:
the GT genotype in locus rs5370 and the 3A4A genotype in locus rs10478694 (P b 0.05 in both cases).
Signiﬁcance: The ET systemsmight play a diseasemodifying role in pediatric NS. Plasma cholesterol, a hallmark of
NS, seems to be associated with genetic variations within the human ET-1 gene.
© 2014 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Animal models in which the human ET-1 gene was transferred into
the germline of mice were established independently by two research
groups (Hocher et al., 1997a,b; Shindo et al., 2002). Both groups
observed similar results: the overexpression of the ET-1 generated a
phenotype characterized by the age-dependent, but blood pressure in-
dependent development of kidney ﬁbrosis, glomerulosclerosis, renal
cysts leading to a progressive decrease in glomerular ﬁltration rate in
agedmice. In these transgenicmodels hypertension canonly be induced
by salt-loading. This was unexpected since previous studies showedFirst Afﬁliated Hospital of Jinan
Science, University of Potsdam,
tal, Germany. Tel.: +49 33200
i-potsdam.de (B. Hocher).
-NC-ND license.ET-1 to be a potent vasoconstrictor when administered intravenously
(Yanagisawa et al., 1988; Hocher et al., 1997a,b). In rats overexpressing
the human ET-2 gene (ET-2 targets the same receptors as ET-1) likewise
a blood pressure-independent ﬁbrotic remodeling of the kidney was
seen but ﬁbrosis is mainly restricted to the glomeruli. This ismost prob-
ably due to the preferential expression of the transgene (human ET-2
gene) within the glomeruli in ET-2 transgenic animals and thus indicat-
ing that a primarily activated glomerular ET systemmay cause protein-
uria (Hocher et al., 1996). Glomerular expression of ET-2 caused
proteinuria in this model, whereas ET-1 transgenic mice with a moder-
ate glomerular transgene expression do not develop proteinuria.
Defects in the glomerular basementmembrane and related cells (for
example podocytes) are considered as causal for development of pro-
teinuria in patents with nephrotic syndrome. Based on the work with
genetically altered animal models, we hypothesized that genetic alter-
ations of the glomerular ET-system might modify manifestation of the
nephrotic syndrome in humans. Genetic association studies in human
with NS might support – but clearly not prove – this hypothesis. In
line with this concept, it was already reported that ET-1 gene
447F. Yang et al. / Life Sciences 118 (2014) 446–450polymorphisms are associated with the morbidity of IgA nephropa-
thy (Maixnerova et al., 2007) and the progression of autosomal dom-
inant polycystic kidney diseases (Reiterova et al., 2006).
In the current study the following three ET-1 gene polymorphisms
were tested: rs5370, rs10478694 (3A4A) and rs 1630736. The functional
signiﬁcance of rs5370 is not clear at this time. Indeed, although theG-to-T
transversion induces a nonsynonymous amino acid change in codon 198
of theprepro-ET-1molecule, codon198 is cleavedout from thebiological-
ly active ET-1 molecule. Alternative causal mechanisms, such as an effect
onmRNA stability,must be considered. Recent association studies suggest
that the Lys198Asn polymorphism interacts with blood pressure in over-
weight people, or with bodymass index (BMI) in associationwith hyper-
tension. The 3A/4A polymorphism (rs10478694) of the ET-1 gene has
signiﬁcant functional importance. Expression studies have shown in-
creased luciferase activity of the insertion variant (I) as compared to the
wild-type (D) variant and the half-life of mRNA containing the insertion
variant is prolonged. In the same study, elevated ET-1 levels were
also reported in the insertion variant as compared to wild type. Sig-
niﬁcant difference in ET-1 levels between 3A/4A and 3A/3A geno-
types has also been reported. This ET-1 gene polymorphism is also
implicated in increased susceptibility to vasovagal syncope. Much
less is known about the rs 1630736 ET-1 SNP. No functional data
are available. However, clinical data suggest an association with
asthma and left ventricular mass in hypertensive patients (Vasku
et al., 2002; Tiret et al., 1999; Sampsonas et al., 2010; Bloch et al.,
1989; Pinto-Sietsma et al., 2003; Asai et al., 2001; Treiber et al.,
2003; Zhu et al., 2008); see Table 4).
Kidney diseases are in general rare during childhood. Primary
nephrotic syndrome (NS) is – among these rare diseases – a fairly
frequent one. Children with NS are usually seen in specialize uni-
versity pediatric nephrology centers. These patients often present
with severe edema, massive proteinuria and hyperlipidemia. Some
of the patients are steroid resistant or steroid dependent, which
are difﬁcult to treat, but its pathogenesis is still not clear. Previous
studies supported that the genetic background may modify disease
pathogenesis/severity in primary NS in children. (Lee et al., 1997;
Shahid et al., 2012; Hinkes et al., 2007; Kobayashi et al., 1995,
2003; Kim et al., 2003; Jafar et al., 2011; Zalewski et al., 2008;
Obeidová et al., 2012; Haeffner et al., 1997). We hypothesize that
the plasma ET-1 concentrations and the ET-1 gene polymorphisms
are associated with the morbidity and the clinical phenotype of
the NS in children.Table 1
Descriptive data in case and control group.
N Case group N Control group P
Age (years) 36 5.80 ± 3.60 94 4.14 ± 1.13 0.01
Gender (male/female) 36 22/14 94 47/47 0.256
Plasma ET-1 concentrations
(pg/ml) a
34 108.9 ± 92.2 67 63.3 ± 20.5 0.007
N5 years 17 82.9 ± 39.0 36 54.7 ± 18.3 0.001
b5 years 17 135.0 ± 120.8 31 73.2 ± 18.4 0.052
a Data are given as mean ± SD. Since 2 blood samples of the 36 cases were hemolytic,
we only have 34 data of plasma ET-1 concentrations in the case group.Patients and methods
Patients
We invited a total of 36 Chinese children with primary nephrotic
syndrome (NS) at the Pediatrics Department of the First Afﬁliated
Hospital and Zhuhai Hospital of Jinan University. The inclusion criteria
were as follows: onset age, b18 years old; patients with proteinuria,
≥50 mg/kg⋅day; and serum albumin, b30 g/l, excluding secondary
NS. Thirty-six children with primary NS formed the case group, including
22 boys and 14 girls. Fourteen cases were steroid resistance NS and 22
cases were non-steroid resistance NS. Twelve cases were with hyperten-
sion and 24 caseswerewith non-hypertension. Renal biopsies were done
in 11 patients, ofwhich 3 caseswithminimal change disease, 3 caseswith
membranous glomerulonephritis, 1 case with mesangioproliferative glo-
merulonephritis and 4 cases with focal segmental glomerulosclerosis.
Ninety-four children, whose urinalysis is normal and who have no past
history of kidney disease, from a kindergarten in Guangzhou were ran-
domly chosen as gene control, of which 67 children's plasma ET-1 con-
centrations were measured as a control. At the same time 24 hour urine
protein output, the plasma creatinine concentrations, blood urea nitrogen
level (BUN) and plasma albumin were measured in NS patients.Reagent and instruments
DNA was puriﬁed from 1.5 ml of blood using the “chlorophenol ex-
traction” method.
Genotyping of the polymorphism in locus rs5370 and rs1630736
The following were the primers used: upstream primer: 5′-TTCCTC
AAGGCAGGGTCACA-3′; downstream primer: 5′-GGGGGAACTCCTTAAC
CTTTCTTG-3′. PCR reaction system (50 μl) was as follows: the reaction
mixture contained 2 μl of genomic DNA, 2 μl of each primer, 4 μl dNTP,
5 μl PCR buffer, 0.25 μl of Taq polymerase (Takara, Biotech, Dalian,
China) and double distilled water to a volume of 50 μl. The cycling condi-
tionswere as follows: after the initial denaturation at 94 °C for 5 minutes,
39 ampliﬁcation cycles were carried out according to the following tem-
perature proﬁle: 30 s at 94 °C, 45 s at 53.7 °C, 50 s at 72. The ﬁnal exten-
sion lasted for 5 minutes at 72 °C.
Genotyping of the polymorphism in locus 3A/4A
The following primers were used: upstream primer: 5′-CAGACGCG
CCTCTGCATCTG-3′; downstream primer: 5′-AGCGTGCCTACCTGTTTC
TG-3. PCR reaction systemwas the same as described above. The cycling
conditions were as follows: after the initial denaturation at 94 °C for
5 minutes, followed by 39 cycles according to the following tempera-
ture proﬁle: 30 s at 94 °C, 45 s at 55.4 °C, 50 s at 72 °C. The ﬁnal exten-
sion lasted for 5 minutes at 72 °C. The product of PCRwas sequenced by
ABI-PRISM 3730 genetic analyzer (Guangzhou Ying-wei biotechnology
corporation).
The plasma ET-1 concentrations were measured by a commercial ra-
dioimmunoassay (Puvevalley Biotech Company, Beijing, China) according
the instructions of themanufacturer. Themain technical indicators are: a)
sensitivity: 15 pg/ml, b) the standard curve range: 20 pg-–200 pg/ml; c)
intra-assay coefﬁcient of variation: b7%, coefﬁcient of variation between
batches: b12%; d) speciﬁcity: the antiserum had no cross-reaction to
motilin, osteocalcin, C terminal parathyroid hormone, calcitonin and
other peptides; e) normal plasma reference values in healthy volunteers
are 50.6 ± 24.5 pg/ml (n= 25).
Statistical analyses
The data are presented as mean ± SD or as a percentage. The chi-
square test was used to test differences in genotype and allele frequen-
cies. T test was used to test the differences in plasma ET-1 concentra-
tions in case group and control group. Completely randomized design
analysis was used to test the differences of clinical indicators in three
different genotypes. P-values b0.05were considered signiﬁcant. All sta-
tistical analyses were performed using SPSS-PC for Windows, Version
16.0. (SPSS Inc., Chicago, IL, USA).
Results
1. The descriptive data of case and control group are provided in
Table 1. The mean age between case group and control group is sig-
niﬁcantly different (5.8 ± 3.59 vs. 4.14 ± 1.12 years).
Table 2
Genotype distribution and plasma ET-1 concentrations of case group and control group in locus rs5370, rs1630736 and 3A/4A.
Case group Control group P (χ2-test comparing allele frequency)
Rs 5370
Genotype GG GT TT GG GT TT
N (alleles) 23 9 4 50 41 3 0.057
Plasma ET-1 concentrations (pg/ml)c 119.0 ± 112.2a 96.0 ± 48.4 85.4 ± 32.5 63. ± 22.4a 63.3 ± 18.5 63.9 ± 18.1
(n) (21) (9) (4) (37) (28) (2)
Rs 1630736
Genotype CC CT TT CC CT TT
N (alleles) 4 19 13 14 43 37 0.74
Plasma ET-1 concentrations (pg/ml)c 85.4 ± 32.5 114.8 ± 108.2 107.4 ± 80.0 63.3 ± 19.5 68.9 ± 23.3 57.03 ± 15.87
(n) (4) +(19) (11) (12) (29) (26)
Rs10478694 (3A4A)
Genotype 3A3A 3A4A 4A4A 3A3A 3A4A 4A4A
N (alleles) 20 14 2 65 29 0 0.041
Plasma ET-1 concentrations (pg/ml)c 131.5 ± 119.6b 81.0 ± 36.1 101.5 ± 29.5 63.4 ± 23.2b 63.1 ± 12.1
(n) (18) (14) (2) (47) (20)
Allele distributions for the three analyzed ET-1 gene variants are given as rawnumbers. Plasma ET-1 concentrations are given asmean ± SD.When comparingplasma ET-1 concentrations
within the case group, there were no signiﬁcant differences between the ET-1 plasma concentrations in relationship to the ET-1 genetic variants of all three tested SNPs. Similarly, there
were no signiﬁcant differences between the ET-1 plasma concentrations in relationship to ET-1 genetic variants within the control group.
Cases with the 3A3A genotype in the Rs10478694 locus had higher plasma ET-1 concentrations as compared to controls with the 3A3A genotype in the Rs10478694 locus. Furthermore,
cases with the GG genotype in the Rs 5370 locus had higher plasma ET-1 concentrations as compared to controls with the GG genotype in the Rs 5370 locus.
a P b 0.05.
b P b 0.05.
c Two blood samples out of 36 cases were hemolytic and could not be analyzed for ET-1 concentrations.
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patients and controls (P= 0.007). This was in particular seen in chil-
dren over the age of 5 years (P= 0.001). Plasma ET-1 concentrations
in general decreased with age (see Table 1).
3. Plasma ET-1 concentrations were not signiﬁcantly associated with
ET-1 genetic variants analyzed in this study (see Table 2). When
comparing plasma ET-1 concentrations in the case group by t test,
there was no signiﬁcant differences between the ET-1 plasma con-
centrations in relationship to ET-1 genetic variants of all three tested
SNPs. Similarly, there were no signiﬁcant differences between the
ET-1 plasma concentrations in relationship to ET-1 genetic variants
of all three tested SNPs in the control group. This was also seen
after adjustment for age, gender, responsiveness to steroids, and hy-
pertension as independent confounding factors. However, caseswith
the 3A4A genotype in the Rs10478694 locus had higher plasma ET-1
concentrations as compared to controls with the 3A3A genotype in
the Rs10478694 locus. Furthermore, cases with the GG genotype in
the Rs 5370 locus had higher plasma ET-1 concentrations as com-
pared to controls with the GG genotype in the Rs 5370 locus (see
Table 2).
4. The allele frequencies between control and NS patients were signiﬁ-
cantly different with respect to the Rs10478694 (3A4A) SNPs of theTable 3
Theurine protein output, plasma creatinine, plasma BUN, plasma cholesterol and plasmaalbumi
Genotype 24 h urine protein output (mg/kg⋅day) Plasma creatinine
rs5370 GG 114.55 ± 133.64(23) 74.54 ± 145.89(2
GT 69.71 ± 35.67(9) 139.27 ± 318.75(
TT 56.26 ± 4.13(4) 31.00 ± 6.68(4)
F 0.84 0.52
P 0.44 0.60
rs1630736 CC 56.26 ± 4.13(4) 31.00 ± 6.68(4)
CT 117.40 ± 143.22(19) 135.13 ± 266.38(
TT 79.34 ± 54.53(13) 35.46 ± 21.07(13
F 0.76 1.17
P 0.48 0.32
Rs10478694 (3A/4A) 3A/3A 79.69 ± 47.86(20) 122.13 ± 258.94(
3A/4A 120.80 ± 167.76(14) 29.78 ± 8.58(14)
4A/4A 101.01 ± 15.30(2) 140.00 ± 132.94(
F 0.56 0.98
P 0.58 0.39
Data are given as mean ± SD, genotype numbers are given in break lets.
Plasma cholesterol was signiﬁcantly (P b 0.05) different when comparing themost frequent ge
(P b 0.05) different when comparing the most frequent genotypes of the Rs10478694 locus (3ET-1 gene, but not with respect to the rs 1630736 ET-1 SNPs. The al-
lele frequencies between control and NS patients for the rs5370 SNP
showed a strong trend for difference (P= 0.057).
5. Plasma cholesterol was signiﬁcantly (P b 0.05) different when com-
paring the most frequent genotypes of the rs5370 locus (GG versus
GT). Similarly, plasma cholesterol was signiﬁcantly (P b 0.05) different
when comparing the most frequent genotypes of the Rs10478694
locus (3A/3A versus 3A/4A). The rs1630736 SNP was not associated
with plasma cholesterol concentrations. Twenty-four hour urine pro-
tein output, plasma creatinine, BUN and albumin were not associated
with the ET-1 gene SNPs (Table 3).
Discussion
Primary NS is a common kidney disease in children. Previous studies
have described an association between ET-1 gene variations and kidney
diseases in adult patients. In the present study, we demonstrated that
plasma ET-1 concentrations in pediatric NS patients were signiﬁcantly
higher as compared to healthy children. We showed that the ET-1 gene
SNP (rs10478694) correlatedwith the risk of NS and correlatedwith plas-
ma ET-1 concentrations when comparing healthy children to children
with NS. Moreover, the ET-1 gene SNPs (rs5370 and rs10478694) aren comparison of three different genotypes in locus rs5370, rs1630736, 3A/4A in case group.
(μmol/l) Plasma BUN (mmol/l) Plasma cholesterol (mmol/l) Plasma albumin (g/l)
2) 7.93 ± 9.68(23) 9.31 ± 2.33(23) 17.00 ± 5.57(23)
9) 10.70 ± 16.02(9) 12.48 ± 3.69(9) 13.13 ± 3.39(9)
4.44 ± 1.34(4) 9.45 ± 2.24(4) 18.15 ± 4.92(4)
0.46 4.54 2.23
0.64 0.02 0.12
4.44 ± 1.34(4) 9.45 ± 2.24(4) 18.15 ± 4.92(4)
18) 10.26 ± 14.51(19) 10.36 ± 3.65(19) 15.32 ± 4.82(19)
) 6.44 ± 4.67(13) 9.98 ± 2.09 (13) 16.79 ± 6.03 (13)
0.72 0.17 0.62
0.49 0.85 0.55
19) 11.42 ± 14.06(20) 9.48 ± 2.07(20) 16.60 ± 4.16(20)
4.18 ± 1.24(14) 11.60 ± 3.21(14) 16.28 ± 6.65(14)
2) 4.66 ± 0.34(2) 6.24 ± 5.14(2) 11.00 ± 1.41(2)
2.01 4.71 1.05
0.15 0.02 0.36
notypes of the rs5370 locus (GG versus GT). Similarly, plasma cholesterol was signiﬁcantly
A/3A versus 3A/4A).
Table 4
Properties of ET-1 SNP's analyzed in the current study.
SNP name Position from start codon Location Alleles Amino acid
changes
rs5370 5771 Exon G/T Lys→ Asn
rs10478694 (3A4A) 138 Intron 3A/4A –
rs 1630736 5503 Intron C/T –
449F. Yang et al. / Life Sciences 118 (2014) 446–450related to the plasma cholesterol level in primary NS of children. Elevated
plasma and tissue concentrations of ET-1 have been associated with the
development of renal interstitial ﬁbrosis and glomerulosclerosis leading
to progressive decrease in glomerular ﬁltration rat (Duan et al., 1999;
Vlachojannis et al., 2002; Cottone et al., 2009; Dhaun et al., 2009; Liu
et al., 1998).
The ET-1gene was assigned to human chromosome 6, in which 191
polymorphic loci have been reported so far. We analyzed three out of
about 200 genetic variants of the ET-1 gene. In the current study the
following gene variants of the ET-1 gene were analyzed: rs5370,
rs10478694 (3A4A) and rs 1630736 (see Table 4 for details and current
knowledge about function and associations to clinical readouts). It was
for example reported that ET-1 gene polymorphism inﬂuenced the pro-
gression of autosomal dominant polycystic kidney diseases (Reiterova
et al., 2006), and they found a signiﬁcantly lower age of onset of ESRD
in the carriers of the 4A allele in combination with the 198N allele in
the carriers of the 4A allele homozygous for the K198 allele.We, howev-
er, could not demonstrate an association of the ET-1 gene SNPs with
markers of disease such as plasma creatinine and BUN in patients with
NS. There might be two reasons. Our study is for sure underpowered
to show this and more importantly the renal function in terms of GFR
in most patients with childhood NS is often normal. Larger adequately
powered prospective studies are needed to demonstrate a potential ef-
fect of ET-1 gene SNPs on disease progression in pediatric NS. The
rs10478694/3A/4A gene polymorphism might affect the transcription
of the ET-1 gene (Vasku et al., 2002). Our results suggested that theplas-
ma ET-1 concentrations are affected by both 3A/4A genotype and the
disease. However the mechanism needs further investigations. We failed
to demonstrate an association between the difference of the plasma ET-1
concentrations and ET-1 gene polymorphisms in locus rs1630736,maybe
because this SNP is functionally less important.
Evidence from both the experiments and clinical studies suggests
that high lipid levels are not only amarker of disease, but also contribute
to the development of glomerulosclerosis (Kees-Folts and Diamond,
1993). The report suggests that cholesterol in children with NS plays
an important role in the progression of the disease. In our study, plasma
cholesterol in NS patients with the GT genotype in locus rs5370 and
with the rs10478694/3A4A genotype in locus 3A/4Awas higher as com-
pared to other genotypes. The ET-1 gene may modulate lipid metabo-
lism via yet unknown pathways. In transgenic animal models (see
Introduction), an activated glomerular ET system causes proteinuria.
In humans, it is more likely that the analyzed genetic variants of the
ET-1 gene play a disease modifying role rather than a causal role. We
need, however, to keep in mind that our study is an association study.
Thus this hypothesis needs to be tested in adequately designed basic sci-
ence experiment able to prove causality.
It is a clear study limitation that controls and cases were not age-
matched. There was a by chance age difference of 1.64 years. The rela-
tively low number of cases and controls, the lack of urine samples to
analyses urinary ET-1 excretion probably more reﬂecting the renal ET-
system, and the lack of a replication cohort are general study limitations
as well. We need to keep in mind that primary pediatric NS is a pretty
rare condition in childhood making it practically very difﬁcult to collect
huge cohorts. However, since comorbidity is less in children, genetic
data coming from these cohorts are less affected by confounding factors.
Genetic association studies in adult patients with NS for example are
confounded by comorbidity such as preexisting diabetes, hypertension,cardiovascular diseases, and atherosclerosis, background medication,
duration of preexisting diseases, and number of preexisting diseases
(children with NS just have NS, adults usually suffer beside NS from
other diseases as well). Thus even smaller pediatric studies may show
clear associations. In any case, our data should be regarded as hypothe-
sis generating study. Another study limitation is the fact that the cross-
reactivity of the ET-1 assay to ET-2, ET-3, Big-E, Big-ET-1, Big-ET-2, and
Big-ET-3 is unknown. This might explain the rather high ET-1 concen-
trations seen in this study.
Conclusions
This study provides the ﬁrst evidence of an association between the
ET-1 gene SNPs and clinical parameters in nephrotic syndrome of chil-
dren, potentially adding new insights into the pathophysiology of child-
hood primary nephrotic syndrome.
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